GCA
KYNB

Gideon Capital Advisors’s Kyntra Bio KYNB Stock Holding History

Gideon Capital Advisors’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-287
Closed -$332K – 400
2018
Q1 		$332K Buy
+287
New +$378K 0.21% 199

Other funds holding KYNB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Gideon Capital Advisors's KYNB Position: Q2 2018 in Review

Gideon Capital Advisors sold out of Kyntra Bio (KYNB) in Q2 2018, closing a stake of 287 shares — an estimated $332K sold.

Gideon Capital Advisors first reported a position in KYNB in Q1 2018 and held it in 1 quarter. The position peaked at $332K in Q1 2018. 192 funds tracked by Wall St. Rank hold KYNB as of Q2 2018.

  • Gideon Capital Advisors reported no remaining Kyntra Bio position as of Q2 2018 after selling out during the quarter.
  • Gideon Capital Advisors sold 287 Kyntra Bio shares in Q2 2018, an estimated $332K.
  • Gideon Capital Advisors first reported a position in Kyntra Bio in Q1 2018 and held it in 1 quarter.
  • Gideon Capital Advisors's Kyntra Bio position peaked at $332K in Q1 2018.
  • 192 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2018.

Based on Gideon Capital Advisors's 13F filing for Q2 2018, filed 8 Aug 2018.